Project Cure & Med Benevolance is categorized under in Houston, TX and active since 2004.
Project Cure & Med Benevolance was established in 2004, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a business, which does work in the B2B market, and is classified as a , under code number 4234502 by the NAICS.
If you are seeking more information, feel free to contact Lane Gibson, Executive Director at the company’s single location by writing to 10250 Westheimer Road, Houston, Texas TX 77042 or by phoning (832) 251-2489. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Project Cure & Med Benevolance |
| Contact Person: | Lane Gibson, Executive Director |
| Address: | 10250 Westheimer Road, Houston, Texas 77042 |
| Phone Number: | (832) 251-2489 |
| Website Address: | projectcure.org |
| Annual Revenue (USD): | $1.000.000 to $2.499.999 |
| Founded: | 2004 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | |
| SIC Code: | 5047 |
| NAICS Code: | 4234502 |
| Share This Business: |
Project Cure & Med Benevolance was started in 2004 to provide professional under the SIC code 5047 and NAICS code 4234502. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.
Feel free to contact Lane Gibson, Executive Director for inquiries that concern Project Cure & Med Benevolance by calling the company number (832) 251-2489, as your correspondence is most welcome. Additionally, the physical location of the single location of Project Cure & Med Benevolance can be found at the coordinates 29.73711,-95.55468 as well as the street address 10250 Westheimer Road in Houston, Texas 77042.
For its online presence, you may visit Project Cure & Med Benevolance’s website at projectcure.org and engage with its social media outlets through on Twitter and on Facebook.